A Patient's Opinion of Unmet Need

Published Online: May 21, 2014
Stanton R. Mehr
What is the sweet spot for the inhaled insulin market? Evidence-Based Diabetes Management interviewed Manny Hernandez, president of the Diabetic Hands Foundation and @Ask Manny, about the market for Afrezza.

EBDM: What is the gap in care that an inhaled insulin might fill?

Hernandez: A very important number of people with type 2 diabetes have avoided “getting to” insulin for years... in no small part because it’s injected. I can’t blame them. I was misdiagnosed with type 2 diabetes back in 2002, and eventually correctly diagnosed as having type 1 (and had to start injecting insulin). It does change you: life is never the same after you have to start taking shots. When you know life without shots, it’s much harder to start them.

In the case of someone with type 1, there’s no option. In the case of so many people with type 2 disease, while there may be options earlier on, there can be a point where it may be ideal to include insulin as part of the treatment. But the “psychological insulin resistance” can be so strong that the person cannot get past it, getting essentially stuck in a place of poorer control, and potentially leading to complications.

This is where inhalable insulin can disrupt things. I do believe we can see a deep impact in terms of control. The 1 thing I look forward to seeing is that it can be affordable to patients who most need it; so another important element to consider is the reimbursement side of things...but that’s a whole other story.

If the inhaled insulin is just as effective as its injected counterpart, to me the fact that it doesn’t need to be injected makes it a very important option to offer to patients.

EBDM: If the FDA does approve Afrezza in July, how do you think patients will react?

Hernandez: If the drug is approved, it will still be a while before it is actually available to patients broadly. Distribution can be challenging. However (assuming it’s approved), once it’s available, the people at MannKind will need to spend important time and energy raising awareness around the new treatment option, because it’s not going to simply be a new insulin, but an altogether new type of insulin delivery that doesn’t involve injections.

I think an important percentage of patients (especially people with type 2 diabetes) will ask their physicians to look into this. I certainly hope physicians listen...but first let’s see what happens in July.
Recommended Articles
Clinical pathways (CPs) are increasingly being utilized to improve quality of care and control healthcare costs in the United States. A new report from Avalere Health examines the development of CPs, use of evidence to inform their design, implementation processes, and their impact on quality of care, costs, and outcomes.
Middle-age men especially were more likely to have undiagnosed diabetes if they suffered from erectile dysfunction, according to the study.
Healthcare spending growth between 2014 and 2024 is projected to be substantially lower than the 3 decades prior to 2008, according to a new report from CMS. In addition, the average premium for a basic Medicare Part D prescription plan will remain stable in 2016.
Patient characteristics and product mix play an important role in determining the overall use and costs of comparable insulins across different manufacturers.
Picking the right measurements to assess improvement in medication management depends largely on the what group is being considered, said Woody Eisenberg, MD, senior vice president of performance measurement and strategic alliances for the Pharmacy Quality Alliance.